stocks logo

FOLD

Amicus Therapeutics Inc
$
6.060
-0.22(-3.503%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.290
Open
6.270
VWAP
6.05
Vol
3.51M
Mkt Cap
1.87B
Low
5.970
Amount
21.20M
EV/EBITDA(TTM)
35.81
Total Shares
296.20M
EV
2.01B
EV/OCF(TTM)
563.22
P/S(TTM)
3.41
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
182.46M
+21.88%
--
--
164.24M
+16.06%
--
--
146.68M
+15.8%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Amicus Therapeutics, Inc. (FOLD) for FY2025, with the revenue forecasts being adjusted by -1.48% over the past three months. During the same period, the stock price has changed by -18.00%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.48%
In Past 3 Month
Stock Price
Go Down
down Image
-18.00%
In Past 3 Month
7 Analyst Rating
up Image
180.53% Upside
Wall Street analysts forecast FOLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FOLD is 17.00 USD with a low forecast of 13.00 USD and a high forecast of 22.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
up Image
180.53% Upside
Current: 6.060
sliders
Low
13.00
Averages
17.00
High
22.00
Morgan Stanley
Equal Weight -> Overweight
upgrade
$12
2025-07-16
Reason
Morgan Stanley upgraded Amicus to Overweight from Equal Weight with a $12 price target.
Morgan Stanley
Morgan Stanley
Equal Weight -> Overweight
upgrade
$102 -> $108
2025-07-16
Reason
Morgan Stanley upgraded Amicus to Overweight from Equal Weight with a price target of $108, up from $102. The firm said it the upgrade is based on its favorable view of Amicus' intellectual property position heading into summary judgment with Aurobindo and longer term confidence in patients switching from Nexviazyme/Lumizyme to PomOp. The firm also noted that the Q1 miss was driven by order timing and the higher UK Voluntary Scheme for Branded Medicines Pricing and Access rebate rate of 22%, compared to the anticipated 12%-15%, reflected in the updated guidance.
Needham
Gil Blum
Hold
Reiterates
n/a
2025-02-20
Reason
Wells Fargo
Tiago Fauth
Buy
Maintains
$18 → $17
2025-02-20
Reason
Wells Fargo analyst Tiago Fauth lowered the firm's price target on Amicus to $17 from $18 and keeps an Overweight rating on the shares. The firm notes the company reported fairly in-line earnings, with no material updates vs pre-announcement. PomOp launch remains the focus of the stock and Amicus continues to execute well with Australia approval recently granted.
Cantor Fitzgerald
Kristen Kluska
Buy
Reiterates
$21
2025-01-15
Reason
Needham
Gil Blum
Hold
Reiterates
n/a
2025-01-13
Reason

Valuation Metrics

The current forward P/E ratio for Amicus Therapeutics Inc (FOLD.O) is -168.33, compared to its 5-year average forward P/E of -2.50. For a more detailed relative valuation and DCF analysis to assess Amicus Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.50
Current PE
-168.33
Overvalued PE
121.47
Undervalued PE
-126.47

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
36.96
Current EV/EBITDA
26.14
Overvalued EV/EBITDA
183.73
Undervalued EV/EBITDA
-109.81

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
7.93
Current PS
2.95
Overvalued PS
11.35
Undervalued PS
4.52

Financials

Annual
Quarterly
FY2025Q1
YoY :
+13.45%
125.25M
Total Revenue
FY2025Q1
YoY :
-63.31%
-7.95M
Operating Profit
FY2025Q1
YoY :
-55.21%
-21.69M
Net Income after Tax
FY2025Q1
YoY :
-56.25%
-0.07
EPS - Diluted
FY2025Q1
YoY :
-123.95%
7.55M
Free Cash Flow
FY2025Q1
YoY :
+4.00%
89.19
Gross Profit Margin - %
FY2025Q1
YoY :
-101.44%
0.30
FCF Margin - %
FY2025Q1
YoY :
-60.53%
-17.31
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
4.0K
USD
1
6-9
Months
259.9K
USD
3
0-12
Months
167.3K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
5.5M
Volume
2
6-9
Months
5.0M
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
3
3.7M
Volume
Months
6-9
1
3.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

FOLD News & Events

Events Timeline

2025-06-25 (ET)
2025-06-25
07:08:43
Amicus announces approval of Pombiliti + Opfolda in Japan
select
2025-06-03 (ET)
2025-06-03
07:06:10
Amicus announces publication of post-hoc analysis of data from PROPEL study
select
2025-05-01 (ET)
2025-05-01
07:07:12
Amicus lowers FY25 total revenue growth view 15%-22% from 17%-24%
select
Sign Up For More Events

News

6.0
07-17SeekingAlpha
Amicus gains as Morgan Stanley upgrades on Aurobindo case and Pom-Op switching
7.0
07-10PRnewswire
SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm
9.0
06-25Newsfilter
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
Sign Up For More News

FAQ

arrow icon

What is Amicus Therapeutics Inc (FOLD) stock price today?

The current price of FOLD is 6.06 USD — it has decreased -3.5 % in the last trading day.

arrow icon

What is Amicus Therapeutics Inc (FOLD)'s business?

arrow icon

What is the price predicton of FOLD Stock?

arrow icon

What is Amicus Therapeutics Inc (FOLD)'s revenue for the last quarter?

arrow icon

What is Amicus Therapeutics Inc (FOLD)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Amicus Therapeutics Inc (FOLD)'s fundamentals?

arrow icon

How many employees does Amicus Therapeutics Inc (FOLD). have?

arrow icon

What is Amicus Therapeutics Inc (FOLD) market cap?